Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Jan;34(1):60-71.
doi: 10.1038/s41433-019-0633-6. Epub 2019 Nov 4.

Treatment choices for newly diagnosed primary open angle and ocular hypertension patients

Anurag Garg  1 , Gus Gazzard  2
Affiliations
Review

Treatment choices for newly diagnosed primary open angle and ocular hypertension patients

Anurag Garg et al. Eye (Lond). 2020 Jan.

Abstract
in English, Chinese

Despite advances in our knowledge of the aetiology and pathophysiology of glaucoma, the sole proven, effective intervention for treating primary open-angle glaucoma (POAG) and ocular hypertension (OHT) remains lowering of intraocular pressure (IOP) to prevent further progression and visual loss. The purpose of this review is to evaluate the treatment choices available to newly diagnosed POAG and OHT patients. We review the existing literature on treatments currently available to newly diagnosed POAG and OHT patients and discuss their role in the treatment paradigm of POAG and OHT. We consider different factors that may be important when offering a choice of treatment to newly diagnosed POAG and OHT patients as well as describing new glaucoma treatments in development and future directions for treatment.

摘要: 尽管我们对青光眼的病因与病理生理学的认识有所提高, 但目前针对原发性开角型青光眼(POAG)和高眼压(OHT)的治疗, 为防止病情进展和视力丧失, 唯一有效的干预措施仍是降低眼内压(IOP)。本文旨在对新诊断的POAG和OHT患者现有的治疗方式进行评估。我们针对新诊断的POAG和OHT患者现有的治疗方式进行了文献回顾, 并讨论了它们在POAG和OHT治疗模式中的作用。我们也考虑了其他因素在治疗新诊断的POAG和OHT中的重要作用。本文也阐述了青光眼治疗方法的新进展以及未来的治疗方向。.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

References

    1. Quigley HA, Broman AT. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006;90:262–7. - PMC - PubMed
    1. Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, et al. Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet (Lond, Engl). 2015;385:1295–304. - PubMed
    1. Kass MA, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol (Chic, Ill : 1960) 2002;120:701–13. - PubMed
    1. Heijl A, Leske MC, Bengtsson B, Hyman L, Bengtsson B, Hussein M. Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol (Chic, Ill : 1960) 2002;120:1268–79. - PubMed
    1. Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E. Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol (Chic, Ill : 1960) 2003;121:48–56. - PubMed

Publication types